OptimizeRx Corporation OPRX R2KPHARMA
Company Overview
OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
Why Investors Should Care
Revenue has grown at a 63.1% CAGR over the past five years.
Trades at a P/E of 21.9, below the sector median of 25.2.
Carries low leverage with a debt-to-equity ratio of 0.18.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $109.43M (+18.8% YoY); net profit $5.13M.
- Trailing 12 Months Year-on-year growth — revenue -9.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 63.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 63.12% |
| 1 Year: | -9.50% |
Stock Price Performance
| 1 Year: | -54.59% |
| 6 Months: | +16.77% |
| 3 Months: | +54.01% |
| 1 Month: | +16.77% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)57.11 · Neutral
P/E of 21.86 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 63.1% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 63.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OPRX OptimizeRx Corporation R2KPHARMA | 7.87 | 21.86 | $147.68M | 0.00% | 7.51% | 5.56% | 63.12% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.10M | 1.10M | 1.23M | 1.29M | 1.43M | 1.82M | 1.49M | 1.71M | 2.01M | 1.76M | 1.91M | 1.79M | 2.15M | 2.87M | 3.10M | 4.11M | 5.10M | 5.42M | 5.21M | 7.01M | 5.00M | 7.58M | 8.78M | 10.52M | 11.23M | 13.63M | 16.12M | 13.73M | 13.98M | 15.09M | 13.00M | 13.82M | 16.33M | 19.69M | 18.81M | 21.31M | 21.93M | 29.20M | 26.07M | 19.84M |
| Gross Profit | 652.59K | - | 843.89K | 728.02K | 696.67K | 861.09K | 731.11K | 823.13K | 962.99K | 866.74K | 990.47K | 1.06M | 770.34K | 1.26M | 1.40M | 2.10M | 2.86M | 3.15M | 3.63M | 4.32M | 3.02M | 4.34M | 5.14M | 6.01M | 6.12M | 8.04M | 9.08M | 8.10M | 8.99M | 9.42M | 7.43M | 7.83M | 9.80M | 12.20M | 11.70M | 13.45M | 13.34M | 18.64M | 17.52M | - |
| Operating Income | 99.83K | 354.12K | -141.61K | -762.20K | -199.86K | -294.85K | -111.50K | -157.53K | 87.57K | -361.83K | -602.51K | -249.22K | -890.44K | -370.56K | -629.66K | -191.20K | 273.60K | 223.18K | 132.16K | 480.04K | -1.99M | -2.26M | -1.06M | -176.72K | -638.31K | 340.14K | 38.19K | -3.76M | -3.91M | -3.76M | -7.06M | -4.85M | -3.55M | -5.03M | -3.75M | -8.56M | -2.10M | 3.19M | 2.05M | 396.00K |
| Net Income | -224.44K | - | -411.73K | -762.10K | -199.44K | -294.54K | -111.20K | -157.22K | 87.94K | -351.92K | -591.93K | -242.58K | -882.68K | -361.50K | -622.79K | -189.18K | 280.51K | 244.93K | 6.53K | 406.62K | -1.57M | -2.20M | -1.08M | -282.89K | -637.38K | 352.10K | 39.89K | -3.76M | -3.88M | -3.47M | -6.40M | -4.16M | -2.87M | -6.90M | -4.01M | -9.12M | -2.20M | 1.53M | 779.00K | -495.00K |
| Diluted EPS | - | - | - | - | - | - | - | - | 0.00 | - | - | - | - | -0.04 | -0.06 | -0.02 | 0.02 | 0.02 | 0.00 | 0.03 | -0.11 | -0.15 | -0.07 | -0.02 | -0.04 | 0.02 | 0.00 | -0.21 | -0.21 | -0.19 | -0.37 | -0.24 | -0.17 | -0.38 | -0.22 | -0.50 | -0.12 | 0.08 | 0.04 | -0.03 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.25M | - | - | 3.40M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 71.06K | 1.11M | 1.99M | 4.68M | 6.50M | 7.22M | 7.75M | 12.13M | 21.21M | 24.60M | 43.31M | 4.52M | 1.02M | 71.52M | 92.13M | 109.43M |
| Gross Profit | - | - | 1.87M | 2.82M | 3.28M | 3.60M | 4.34M | 5.95M | 12.21M | 15.44M | 24.11M | 35.64M | 38.97M | 42.90M | 59.38M | 73.59M |
| Operating Income | -1.85M | -1.45M | -454.92K | -267.54K | -1.03M | -597.41K | -1.58M | -2.13M | 180.13K | -3.69M | -2.14M | 361.10K | -12.29M | -26.40M | -13.71M | 11.69M |
| Net Income | - | -2.12M | -454.55K | -267.29K | -1.03M | -595.14K | -1.54M | -2.10M | 226.34K | -3.14M | -2.21M | 378.08K | -11.44M | -17.57M | -20.11M | 5.13M |
| Diluted EPS | - | - | - | - | - | - | - | -0.21 | 0.02 | -0.23 | -0.15 | 0.02 | -0.64 | -1.03 | -1.10 | 0.27 |
| R&D Expense | - | - | - | - | - | - | - | - | 0 | 1.60M | 0 | - | - | - | 0 | 0 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 3.75M | 2.89M | 2.18M | 3.95M | 7.03M | 12.31M | 11.48M | 9.76M | 25.05M | 56.64M | 60.33M | 140.99M | 134.65M | 183.37M | 171.17M | 176.92M |
| Total Equity | 1.89M | 1.59M | 1.40M | 1.67M | 4.61M | 8.94M | 7.81M | 6.22M | 18.46M | 44.86M | 49.97M | 131.38M | 126.11M | 126.55M | 117.00M | 128.29M |
| Cash & Equivalents | 1.28M | 959.17K | 284.26K | 1.12M | 3.45M | 8.21M | 7.03M | 5.12M | 8.91M | 18.85M | 10.52M | 84.68M | 18.21M | 13.85M | 13.38M | 23.36M |
| Long Term Debt | 1.00M | 0 | - | - | - | - | - | - | - | - | - | - | - | 34.23M | 30.82M | 21.42M |
| Total Liabilities | 1.85M | 1.30M | - | - | - | - | - | 3.54M | 6.60M | 11.78M | 10.35M | 9.61M | 8.54M | 56.82M | 54.17M | 48.62M |
| Current Liabilities | 854.83K | 1.30M | 770.52K | 2.28M | 2.42M | 3.37M | 3.67M | 3.54M | 4.23M | 6.11M | 10.03M | 9.37M | 8.40M | 17.88M | 18.65M | 21.26M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.31M | -521.51K | -624.03K | 1.13M | -56.35K | 515.11K | -465.96K | -1.48M | 792.55K | -1.66M | -6.31M | 726.04K | 10.65M | -7.24M | 4.89M | 18.71M |
| Investing Cash Flow | -225.64K | -239.92K | -50.87K | -298.65K | -409.95K | -100.96K | -349.54K | -42.24K | -5.69M | -10.58M | -124.72K | -486.00K | -58.18M | -25.34M | -450.00K | 68.00K |
| Financing Cash Flow | 2.16M | 442.50K | 0 | 0 | 2.80M | 4.35M | -357.42K | -390.00K | 8.69M | 22.18M | -1.90M | 73.92M | -18.95M | 28.22M | -4.91M | -8.80M |
| Capital Expenditure | 1.23K | -13.10K | -2.23K | -0 | -6.98K | -2.05K | -178.43K | -42.24K | -34.36K | -87.72K | -68.04K | -100.32K | -81.00K | -87.00K | -112.00K | -58.00K |
| Free Cash Flow | -1.31M | -534.61K | -626.26K | 1.13M | -63.33K | 513.06K | -644.40K | -1.52M | 758.19K | -1.75M | -6.38M | 625.72K | 10.57M | -7.33M | 4.78M | 18.66M |
| Share Buybacks | - | - | - | - | - | - | 806.91K | 390.00K | - | - | - | - | 20.02M | 7.52M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 94.2% | 60.2% | 50.5% | 49.8% | 56.0% | 49.1% | 57.6% | 62.8% | 55.7% | 789.0% | 3,801.6% | 60.0% | 64.5% | 67.3% |
| Operating Margin % | -2,597.9% | -130.8% | -22.9% | -5.7% | -15.8% | -8.3% | -20.4% | -17.6% | 0.8% | -15.0% | -4.9% | 8.0% | -1,199.1% | -36.9% | -14.9% | 10.7% |
| Net Margin % | - | -190.8% | -22.9% | -5.7% | -15.8% | -8.2% | -19.9% | -17.3% | 1.1% | -12.8% | -5.1% | 8.4% | -1,115.9% | -24.6% | -21.8% | 4.7% |
| ROE % | - | -133.5% | -32.4% | -16.0% | -22.2% | -6.7% | -19.7% | -33.8% | 1.2% | -7.0% | -4.4% | 0.3% | -9.1% | -13.9% | -17.2% | 4.0% |
| ROCE % | -63.8% | -91.5% | -32.4% | -16.0% | -22.3% | -6.7% | -20.2% | -34.2% | 0.9% | -7.3% | -4.2% | 0.3% | -9.7% | -16.0% | -9.0% | 7.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Whetstone Capital Advisors, LLC | 12.47% | 1.51M | $11.99M |
| 2 | Royce & Associates LP | 9.01% | 1.09M | $8.66M |
| 3 | Vanguard Capital Management LLC | 5.78% | 699.60K | $5.56M |
| 4 | Kennedy Capital Management, LLC | 5.33% | 644.15K | $5.12M |
| 5 | Rice, Hall, James & Associates LLC | 5.24% | 633.84K | $5.04M |
| 6 | BLAIR WILLIAM & CO/IL | 5.03% | 607.92K | $4.83M |
| 7 | AQR Capital Management, LLC | 4.83% | 583.96K | $4.64M |
| 8 | Dimensional Fund Advisors LP | 3.95% | 477.69K | $3.80M |
| 9 | Blackrock Inc. | 3.68% | 445.38K | $3.54M |
| 10 | Parkman Healthcare Partners LLC | 2.90% | 350.35K | $2.79M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OPRX
Understanding Momentum Shifts in (OPRX) - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNV0ZTck5kRUlyZFE0MDEyTVNuNjYzMW44enpWeFV6NERKN1JPVGZiakVDSlRWX1QzX1VhSGl4MHN6SVRGMmxPQlFFcXpKSFppWklVWHZMOXdUTUF6NnVHaFNyeVg3RGFNMWNrOTFlbFA0VGJRNUFGTV9TcElWNGZoS2dNR0ZFaXZnUWtxV2…
OptimizeRx (OPRX) Stock Sees Fair Value Cut As Analysts Reset Growth Expectations - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOazhjcnlydE1uQTIwWDJZX0N0T1VpM2xhTXpRbGxfZ2FhT3Nwak56MHFwaURGZjkxWUtQeklZUnhtdG0xSjR0ZDFvTDdsRWp5dENCRlpkNW9qU0FsNjZwaWRId3g1OGxsMTZBRHU4MWRqQ2VkcHFENDlueXV4LXAzTVpWdTZUZjJRUkpPYU…
Johnson & Johnson’s former data chief joins OptimizeRx to guide AI tools - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPdnpNMm1DSHNsQ0Nsei15UldhTkhjQzhRZTlwM294bGVSN3d3cERlOHR2VnN4dmliWnptQ25NMFpxaDM0UkRWZzFKRHcwMTM0TEJCaWl3ekhWSGVqS1FKOUNQMFI4NmZxS0NlbTdHVUxhS2RpVDlvVkx6VUNCdTludEhVREk4UmJaekRqcH…
OptimizeRx (OPRX) Stock Grapples With Revenue Slump Despite Margin Progress - webull.com
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE82OWh4d1J6VW5rQmRuZHNzdFNMZXJ4X0NycjdZVExNSFRSb2lrNDBRMkNMX0w3M0xLdk9jdi1SdmNtYXVsSkZGQjBSbXRtVmdrVGdkT2xKZzk?oc=5" target="_blank">OptimizeRx (OPRX) Stock Grapples With Revenue Sl…
OptimizeRx (OPRX) Stock Grapples With Revenue Slump Despite Margin Progress - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPTjJycmlqcFlQeU41c0IyRGkzb0hYbmlDU2FXUFR0S1JfNHdadW9vMHF6czA1aTlUT19kNHNkalVJV0RjQzJmMlBaekkxeFNSQ2gyc0kwc2FWZzBGVWdnVVVfbzM2Y3dpRHZ0aHQwVFg1djA5Z2tFakpLNzRFcklKbENtU05PMW9GMllOVV…
OPRX | OptimizeRx Corporation Common Stock Financials - Revenue Breakdown - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE1XNHE2azhhTkZJUzJDR1A4SENmMWpId1p1dE5fZXBGRE1fSUlSTU5yaTg0Um5WNHpMcE5ZY3BCNHA4OVVPUXVXaXRFNTA4ekpTajhRckZoZDlzMmNZV1ZlZ29SeTQ0c0RBUERVN056OUl1SEVaemRN?oc=5" target="_blank">OPRX | …
OPRX — Frequently Asked Questions
What is the current share price of OptimizeRx Corporation (OPRX)?
As of 2026-09-07 16:24 PDT, OptimizeRx Corporation (OPRX) trades at $7.87 on NasdaqCM. Its 52-week range is $4.54 to $21.68.
What is the market capitalisation of OPRX?
OptimizeRx Corporation (OPRX) has a market capitalisation of $147.68M on NasdaqCM.
What is the P/E ratio of OPRX?
OPRX trades at a trailing price-to-earnings (P/E) ratio of 21.86. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.03.
What is the return on equity (ROE) of OPRX?
OPRX has a return on equity (ROE) of 5.56%. Its return on capital employed (ROCE) is 7.51%.
Is OPRX a good stock to buy?
This page provides a data-driven analysis of OptimizeRx Corporation (OPRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.